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Objective: Dedifferentiation could explain reduced functional pancreatic b-cell mass in type 2 diabetes (T2D).
Methods: Here we model human b-cell dedifferentiation using growth factor stimulation in the human b-cell line, EndoC-bH1, and human
pancreatic islets.
Results: Fibroblast growth factor 2 (FGF2) treatment reduced expression of b-cell markers, (INS, MAFB, SLC2A2, SLC30A8, and GCK) and
activated ectopic expression of MYC, HES1, SOX9, and NEUROG3. FGF2-induced dedifferentiation was time- and dose-dependent and reversible
upon wash-out. Furthermore, FGF2 treatment induced expression of TNFRSF11B, a decoy receptor for RANKL and protected b-cells against
RANKL signaling. Finally, analyses of transcriptomic data revealed increased FGF2 expression in ductal, endothelial, and stellate cells in pancreas
from T2D patients, whereas FGFR1, SOX,9 and HES1 expression increased in islets from T2D patients.
Conclusions: We thus developed an FGF2-induced model of human b-cell dedifferentiation, identiﬁed new markers of dedifferentiation, and
found evidence for increased pancreatic FGF2, FGFR1, and b-cell dedifferentiation in T2D.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Type 2 diabetes develops as a consequence of a combination of insulin
resistance and insufﬁcient b cell mass. The decline in b cell mass has
been attributed to a decrease in both b cell number and function [1]. It
has been suggested that decreased b cell mass is the result of pre-
mature programmed cell death and research efforts focused on
increasing b cell survival [2]. However, recent data challenge the b cell
death hypothesis. These data suggest that b cell dedifferentiation
represents an alternative mechanism to explain loss of functioning b
cells [3]. During dedifferentiation, b cells do not undergo apoptosis.
Rather, they lose identity and function with a decrease in expression of
key b cell markers such as genes encoding major transcription factors,
e.g. MafA, and proteins implicated in glucose-stimulated insulin
secretion, e.g. Slc2a2 (Glut2) [4].
This concept of b cell dedifferentiation is now strongly supported by
experiments performed in several murine models and based on
lineage-tracing of b cells [3,5]. On the other hand, data on human b
cell dedifferentiation remain scarce and mainly based on experiments
performed on static models such as human pancreatic tissue sections.
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www.molecularmetabolism.compancreata from type 2 diabetic donors contain degranulated b cells
that are depleted of insulin [6]. Pancreatic sections of type 2 diabetic
patients demonstrated a 3-fold increase in the number of endocrine
cells (Chromogranin A-positive) that stain negative for insulin,
glucagon, somatostatin, or pancreatic polypeptide [7]. Such dediffer-
entiated human b cells, however, expressed the endocrine progenitor
cell marker aldehyde dehydrogenase 1A3 (ALDH1A3) [7].
Our study aimed at developing a dynamic model of human b cell
dedifferentiation. Access to preparations of primary human b cells is
limited and human-translatable models to study their dedifferentiation
are lacking. Here, we used EndoC-bH1, a recently developed func-
tional human b cell line that was generated by lentiviral transduction of
human fetal pancreas with oncogenes expression driven by the insulin
promoter [8]. This line represents an efﬁcient tool to study human b
cells in pathophysiological conditions [8e10].
Our work speciﬁcally aimed at: i). Discovering molecules and pathways
that induce human b cell dedifferentiation ii). Discovering new positive
markers of human b cell dedifferentiation iii). Deﬁning whether human
b cell dedifferentiation is a reversible process and iv). Identifying new
evidences of dedifferentiation in human islets from type 2 diabetic
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Original Articlegrowth factor family, ﬁbroblast growth factor 1 (FGF1) and ﬁbroblast
growth factor 2 (FGF2), induce human b cell dedifferentiation, in a
reversible manner. We also identiﬁed several transcription factors,
SOX9, HES1, MYC, and TNFRSF11B, as new positive markers of hu-
man b cell dedifferentiation and showed that pancreata from type 2
diabetic patients display sustained expression of both FGF2/FGFR1 and
our novel markers of dedifferentiation.
2. METHODS
2.1. Culture of human b cell lines and treatments
EndoC-bH1 cells were cultured in low-glucose (5.6 mM) Dulbecco’s
modiﬁed Eagle’s medium (DMEM; SigmaeAldrich) containing 2% BSA
fraction V (Roche), 50 mM 2-mercaptoethanol (SigmaeAldrich), 10 mM
nicotinamide (Calbiochem), 5.5 mg/ml human transferrin (Sigmae
Aldrich), 6.7 ng/ml sodium selenite (SigmaeAldrich), and 100 units/
mL Penicillin and 100 mg/mL Streptomycin (ThermoFischer Scientiﬁc)
as previously described [8]. Cells were seeded at a density of 9.104
cells/cm2 on Matrigel (1.2%; SigmaeAldrich) and Fibronectin (3 mg/
ml; SigmaeAldrich) -coated plates and cultured at 37 C in 5% CO2.
EndoC-bH1 cells were treated with either recombinant human FGF1
(100 ng/mL) plus heparin sodium salt (2 mg/mL) (both from Sigmae
Aldrich), recombinant human FGF2 (100 ng/mL, Peprotech), recom-
binant human Soluble RANK Ligand Protein (Merck Millipore), re-
combinant Human Osteoprotegerin/TNFRSF11B Protein (R&D
Systems), or U0126 (Calbiochem).
2.2. Human islets
Human islets were obtained from 8 donors (from M.A., Paris; LM and
PM, Pisa; and commercially from Prodo Laboratories Inc.). They were
cultured during three days in medium supplemented with either FGF2
or with the FGF2 carrier (PBS-BSA 0.2%).
2.3. RNA isolation, reverse transcription, and real-time PCR
RNeasy Micro kit (Qiagen) was used to extract total RNA from EndoC-
bH1 cells and from human islets. Maxima First Strand cDNA synthesis
(ThermoFischer) was used to synthesize cDNA. Quantitative RT-qPCR
was performed using Power SYBR Green mix (Applied Biosystems)
with a QuantStudio analyzer (Applied Biosystems). Custom primers
were designed with NCBI Primer-BLAST [11] and their efﬁciency was
determined following serial dilutions of cDNA samples from EndoC-
bH1-cells or human islets. Cyclophilin-A transcript levels were used for
normalization. The list of primers is presented in Table S1.
2.4. Transcriptome analysis
Total RNA was isolated using RNeasy Micro kit (Qiagen). The quality of
the RNA was assessed by a Fragment Analyzer (Advanced Analytical
Technologies). One microgram of total RNA was used for each library.
The RNA samples were processed with Illumina TruSeq Stranded
mRNA Library prep kit following the manufacturer’s recommendations.
Libraries were quantiﬁed with Qubit HS (ThermoFisher) and Fragment
Analyzer (Advanced Analytical Technologies). Indexed libraries were
pooled and sequenced on an Illumina NextSeq 500 high-output run
using paired-end chemistry with 75 bp read length.
2.5. Processing of RNA-Seq data and differential expression
analysis
Paired-end reads were generated using an Illumina NextSeq 500 and
processed using the RNA-seq pipeline implemented in the bcbio-
nextgen project [https://bcbio-nextgen.readthedocs.org/en/latest/].2 MOLECULAR METABOLISM- (2018) 1e13  2018 The Authors. Published by Elsevier GmbH. ThiReads were aligned to the human genome version hg38 using the
Hisat2 aligner [12].
Counts of reads aligning to known genes are generated by featur-
eCounts [13]. Differential expression analysis was performed using
DESeq2 [14]. All data are MIAME compliant, and the raw data have
been deposited in a MIAME compliant database (GEO, accession
number GSE103383).
2.6. Analysis of published transcriptomes
Raw data from GSE25724 microarray study was downloaded from the
GEO database. Differential gene expression was assessed as previ-
ously described [15,16]. The moderated t-statistics within the limma
package were used to obtain p-values for differential expression of
genes under investigation [17]. If multiple probes mapped to the same
gene, only the probe with smallest p-value was retained. Given the
small number of individual hypothesis tests, we did not further adjust
p-values for multiple testing.
For the single-cell RNA sequencing studies (E-MTAB-5061), we
downloaded fastq ﬁles from the GEO database and aligned them to
human genome version hg38 using the hisat2 aligner [12], followed by
quantitation using the Salmon algorithm [18] and cpm (counts per
million) normalization. Differential expression analysis was carried out
using the MAST (model-based analysis of single-cell transcriptomics)
R-package [19]. In addition to the number of detected genes per cell
and disease condition, we included ethnicity and gender as covariates
in the model to prevent erroneous differential expression calls due to
different ethnicity or gender distributions in the control and case group.
P-values were then derived from a likelihood ratio test carried out with
the generalized linear model parameters of the case and control group.
2.7. Immunostaining of EndoC-bH1 cells and primary pancreatic
islets
EndoC-bH1 cells were cultured on 12-mm Matrigel/ﬁbronectin-coated
glass coverslips. They were treated with FGF2 for 3 days, ﬁxed for 1 h
with 4% paraformaldehyde, permeabilized, and stained with a rabbit
anti-SOX9 antibody (1/500; Millipore) that was revealed with a Goat
anti-Rabbit IgG Alexa Fluor 488 conjugate (Life Technologies). Human
pancreatic islets were treated for 72 h with FGF2 and ﬁxed in 3.7%
formaldehyde prior to embedding in parafﬁn. Sections (4-mm thick)
were prepared and processed, as described [20]. The sections were
stained with the following antibodies: mouse antiechromogranin A (1/
50; Dako Cytomation); rabbit anti-SOX9 antibody (1/500; Millipore).
The secondary antibodies were Goat anti-Rabbit IgG Alexa Fluor 488
conjugate (Life Technologies) and Goat anti-mouse IgG Alexa Fluor 594
conjugate (Jackson ImmunoResearch). Digital images of EndoC-bH1
cells were captured using a cooled 3-chip charge-coupled device
camera (Hamamatsu C5810; Hamamatsu) that was attached to a
ﬂuorescent microscope (Leica; Leitz).
2.8. Western blot analyses
Protein lysates prepared in RIPA buffer were subjected to immuno-
blotting. The following antibodies were used: MAFA (1/500; a gift from
Dr. Rezania, BetaLogics Venture, New Jersey, USA), SOX9 (1/500;
Millipore), HES1 (1/1,000, Cell-Signaling), ZNT8 (1/1,200, clone
17H2.4 generously provided by Dr. Davidson, Barbara Davis Center,
Denver, Colorado), PDX1 (1/2,000; [20]), phospho-P38 MAPK (1/
1,000; Cell Signaling), P38 MAPK (1/1,000, Cell Signaling), and
TUBULIN (1/2,000; SigmaeAldrich). Species-speciﬁc HRP-linked
secondary antibodies (Cell Signaling) were added on the membrane
and visualization was performed on an ImageQuant LAS 4000s is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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following ECL exposure (GE Heatlhcare). Quantiﬁcations were
normalized by TUBULIN expression.
2.9. Luciferase reporter assays
EndoC-bH1 cells were transfected with 950 ng insulin promoter driven
reporter and 50 ng pGL4.72-TK[hRlucCP] (Renilla luciferase, Promega)
per well of 12 well plate using 3 ml of Lipofectamin2000 (Life Tech-
nologies) [21]. Three hours later, the transfection medium was
changed for culture medium containing either the carrier (PBS-BSA
2%), or FGF1 (100 ng/mL) or FGF2 (100 ng/mL). Luciferase activities
were measured 72 h later using the Dual-Luciferase reporter assay
system (Promega) following manufacturer’s instructions. Fireﬂy lucif-
erase activities were normalized to Renilla luciferase activities to
correct for variation in transfection efﬁciency.
2.10. Insulin content
EndoC-bH1 cells were lysed by overnight incubation at 20 C in
ethanol (75%)/HCl (1.5%), centrifuged at 2,000rpm for 15 min at 4 C
and stored at 20 C. Insulin contents were measured in triplicate by
ELISA according to the manufacturer’s instructions using the human
insulin kit (Mercodia).
2.11. Zinc staining
EndoC-bH1 cells were seeded in 96 wells plates and allowed to attach
for 24 h before treatment with 100 ng/mL FGF2. After 72 h, cells were
treated with 30 mM KCl for 15 min to induce acute degranulation. They
were rinsed, and fresh media containing 100 ng/mL FGF2 was added
for another 72 h. Following treatment, cells were rinsed in PBS and
stained with the zinc-speciﬁc ﬂuorescent probe Zinpyr-1 (5 mM,
Cayman Chemical), which stains primarily zinc-enriched secretory
granules in beta cells [22]. Cells were then observed using confocal
microscopy using a 488 nm laser line for excitation and 525/50 nm
emission wavelength. Image analysis was performed using the
Colombus software (PerkinElmer).
2.12. Statistical analysis
Data are expressed as mean  SD. Analyses were carried out using
SigmaStat 3.5 (Systat Software, San Jose, CA, 8 USA). Differences
between groups were evaluated using non-parametric tests, namely
ManneWhitney U test for non-paired analyses and Wilcoxon test for
analysis of paired data. Statistical signiﬁcance was set at p < 0.05.
3. RESULTS
3.1. FGF2 treatment decreases INS and MAFA expression in
EndoC-bH1
We ﬁrst tested whether EndoC-bH1 could be used to discover com-
pounds that modulate b cell differentiation status. For this purpose, we
treated EndoC-bH1 with molecules acting through different pathways:
ligands of receptor tyrosine kinases (FGF1, FGF10, IGF1, EGF), a G-
protein coupled receptor ligand (Exendin-4), a ROCK-1 inhibitor (Y-
27632), an activator of the WNT/b catenin pathway (R-Spondin) and a
modulator of the TGF-beta signaling (Noggin). We measured the
expression of INS and MAFA, a b cell speciﬁc transcriptional activator.
We observed that following 72 h treatment, FGF1 induced a 2-fold
decrease in INS mRNA levels while MAFA mRNA levels dropped
down by more than 10 fold (Figure 1A,B).
FGF1 is a member of the Fibroblast Growth Factor family that signals
through each of the 7 FGF receptors (FGFR) [23]. Interestingly, the
effect of FGF1 on INS and MAFA mRNA levels was mimicked by FGF2
(Figure 1C), which belongs to the same subfamily of FGFs, but notMOLECULAR METABOLISM- (2018) 1e13  2018 The Authors. Published by Elsevier GmbH. This is an ope
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[24]. Both FGF1- and FGF2-treated cells showed a reduction in the
activity of the human insulin promoter as compared to control cells,
supporting a role for both factors as negative regulators of INS gene
transcription (Figure 1D). RT-qPCR analyses indicated that EndoC-bH1
mainly express FGFR1c, FGFR3b, and FGFR4 (Figure 1E). As FGF2
signals preferentially through the c-forms of FGFRs [23], it can be
postulated that in EndoC-bH1, FGF1 and FGF2 act through FGFR1c to
modulate INS and MAFA gene expression. Finally, FGF treatment did
not signiﬁcantly modify cellular growth and survival during the 3-days
culture period (Figure 1FeH).
3.2. Decreased expression of several master b cell genes following
FGF1 and FGF2 treatments
We treated EndoC-bH1 with FGF2 and performed global transcriptomic
analyses by RNA-Seq at different time points (24 h-144 h treatments).
We ﬁrst searched for genes implicated in b cell function, with decreased
expression following treatment with FGF2. As expected, INS and MAFA
mRNA levels decreased. This was also the case for transcription factors
expressed in b cells such as MAFB, PAX6, NEUROD1, RFX6, INSM1 but
also for factors implicated in insulin processing and secretion such as
PCSK2, SLC2A2 GCK, and SLC30A8 (ZNT8) (Figure 2A and Table S2).
These data were conﬁrmed by RT-qPCR using either FGF2 or FGF1
(Figure 2B). Both FGF1 and FGF2 repress the expression of b cell
speciﬁc genes in a time- and concentration-dependent manner
(Figs. S1 and S2). Following treatment with either FGF1 or FGF2, we
also observed a sharp decrease in total cellular insulin content as
measured by ELISA (Figure 2C), while western blot analyses indicated
decreased levels of both the transcription factor MAFA and the b cell
enriched zinc transporter ZNT8 (Figure 2D). Interestingly, we could also
measure the functional consequences of decreased ZNT8 expression,
as shown by a signiﬁcant reduction in granular zinc content in EndoC-
bH1 (Figure 2E). Of note, while the expression of several b speciﬁc
markers collapsed, other b or endocrine markers remained expressed
following FGF treatment. Similarly, the transcription factor PDX1 shows
limited decrease at the RNA and protein level (Figure 2F,G). This is also
the case for b cell-speciﬁc marker such as IAPP and endocrine markers
such as CHROMOGRANIN A and ABCC8 (Figure 2F and Table S2). Taken
together, while keeping their global endocrine feature, EndoC-bH1
loose a number of b cell-speciﬁc markers following FGF treatment.
3.3. FGFs treatment induces ectopic gene expression in EndoC-
bH1
Our global transcriptomic analysis indicated that in parallel to the
extinction of a number of b cell speciﬁc genes, treatment of EndoC-
bH1 with FGF2 sharply induced ectopic gene expression. This was the
case for three transcription factors: SOX9, HES1, and MYC (Figure 3A).
We conﬁrmed these transcriptomic data using FGF1 and FGF2 by RT-
qPCR (Figure 3B) and by western Blot and immunostaining
(Figure 3C,D). Both FGF1 and FGF2 induced ectopic gene expression in
a time- and concentration-dependent manner (Figs. S1 and S2). This
effect was blocked when the cells were pre-treated with the MEK
inhibitor U0126 (Fig. S3). FGF2 treatment also increased ectopic
expression of GAST (gastrin), which encodes a peptide hormone found
in islets during fetal life, but absent during adult life [25] and PYY, an
anorexigenic hormone usually not found in human b cells but rather
produced by intestinal L cells [26] (Figure 3E,F). Interestingly, FGF
treatment also induced the expression of the pancreatic endocrine
progenitor marker NEUROG3 also usually absent from mature human b
cells [27] (Figure 3E,F). Induction of endocrine progenitor markers was
also observed by comparison with a published list of pancreaticn access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 3
Figure 1: FGF1 and FGF2 treatments decrease INS and MAFA expression in EndoC-bH1. (A, B) EndoC-bH1 cells were exposed to the indicated treatments for 3 days.
INSULIN and MAFA mRNA were measured by RT-qPCR. (C) Both FGF1 and FGF2 decrease INS and MAFA mRNA levels. (D) Human insulin promoter (HIP) activity was determined
after transient transfection of EndoC-bH1 cells with the reporter vector HIP-Luc2CP followed by 3 days treatment with FGF1 or FGF2. (E) Expression by qPCR of human FGFR
isoforms in EndoC-bH1 cells. (F, G, H) A 72 h treatment of EndoC-bH1 cells with FGF2 does not modify cell survival, growth or morphology (scale bar: 100 mm). Data are
represented as mean  SD. n ¼ 5 biological replicates. **p < 0.01, ***p < 0.001.
Original Articleendoderm enriched genes (Table S3) [28] (Figure 3G, horizontal axis).
Moreover, temporal analysis revealed that loss of b cell speciﬁc genes
(Table S4) preceded the induction of progenitor cell genes: b cell genes
expression decreased as early as 24 h treatment, while progenitor
genes were induced from 72 h and more intensely at 144 h in parallel
with a collapse of b cell genes (Figure 3G).4 MOLECULAR METABOLISM- (2018) 1e13  2018 The Authors. Published by Elsevier GmbH. ThiOn the other hand, the expression of acinar (AMY2B, CPA1) and duct
(CFTR, SPP1) markers was very low in control condition and not
induced by FGF treatment (Fig. S4). A lack of induction was also
observed for endocrine markers such as GCG, NPY, and GHRL with the
exception of SST, whose expression was induced by FGF1 and FGF2
(Figure 3H).s is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 2: FGF1 and FGF2 treatments decreased the expression of several master b cell genes. (A) mRNA levels of b cell markers in EndoC-bH1 are decreased by FGF2 in a
time-dependent manner as assessed by RNA-Seq. (B) Similar results were obtained using either FGF1 or FGF2 as measured by RT-qPCR. (C) Insulin content (ng per 106 cells) after
6 days of treatment with FGF1 or FGF2 determined by ELISA. (D) Western-Blot analyses of MAFA and ZNT8 levels after 3 days of treatment with FGF1 or FGF2. (E) Quantiﬁcation of
granular zinc staining using the zinc-speciﬁc ﬂuorescent probe Zinpyr-1. (F) FGF1 and FGF2 treatments do not decrease PDX1, ABCC8, and CHGA mRNA levels as assessed by RT-
qPCR. (G) Western-Blot analyses of PDX1 levels after three days of treatment with FGF1 or FGF2. Data are represented as mean  SD. n ¼ 5 biological replicates. *p < 0.05,
**p < 0.01, ***p < 0.001. AU: Arbitrary Units.3.4. Dedifferentiation is a reversible state
We treated EndoC-bH1 for 3 days with FGF2 to induce dedifferentia-
tion. We next performed a chase culture period of 11 days in theMOLECULAR METABOLISM- (2018) 1e13  2018 The Authors. Published by Elsevier GmbH. This is an ope
www.molecularmetabolism.comabsence of FGF2 in order to address whether dedifferentiation repre-
sents an irreversible new state or whether it can be reversed. As
expected, INS and MAFA mRNA levels dramatically decreased whilen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 5
Figure 3: FGFs treatments induce ectopic gene expression in EndoC-bH1. (A) mRNA levels of SOX9, HES1, and MYC in EndoC-bH1 are induced by FGF2 in a time-dependent
manner as assessed by RNA-Seq. (B) Similar results were obtained by RT-qPCR using either FGF1 or FGF2 (72 h treatment). (C) Western-Blot analyses of SOX9 and HES1 levels
after three days of treatment with FGF1 or FGF2. (D) Immunoﬂuorescence analysis of SOX9 expression EndoC-bH1 cells. Nuclear expression of SOX9 (in green) is observed
following 72 h treatment with FGF2. Nuclei are stained with Hoechst 33342 stain (blue). Scale bar, 15 mm. (E) mRNA levels of GAST, PYY and NEUROG3 in EndoC-bH1 are induced
by FGF2 in a time-dependent manner as assessed by RNA-Seq. (F) GAST and NEUROG3 data were conﬁrmed by RT-qPCR using either FGF1 or FGF2 (72 h treatment). (G) Average
expression (TPM) of b cell speciﬁc genes vs. progenitor genes (genes lists in Tables S2 and S3) assessed by RNA-Seq after treatment of EndoC-bH1 with FGF2. (H) The expression
pancreatic hormones (GCG, NPY, GHRL) are not induced by a 72-hour treatment with either FGF1 or FGF2, with the exception of SST. Data are represented as mean  SD. n ¼ 5
biological replicates **p < 0.01, ***p < 0.001.
Original ArticleSOX9 and HES1 mRNA levels were strongly induced following 72 h or
14 days of treatment with FGF2 (Figure 4). Importantly, when FGF2
was removed at day 3 and EndoC-bH1 further cultured for 11 days in
the absence of FGF2, INS, MAFA, SOX9, and HES1 mRNA levels
returned to control values, demonstrating that dedifferentiation rep-
resents a reversible state.6 MOLECULAR METABOLISM- (2018) 1e13  2018 The Authors. Published by Elsevier GmbH. Thi3.5. Dedifferentiated b cells express TNRFSF11B (OPG)
By mining our transcriptomic data, we discovered that FGF2 treatment
induced the expression of TNRFSF11B mRNA levels (Figure 5A). Such
an induction of TNRFSF11B by FGF2 was conﬁrmed by RT-qPCR in
EndoC-bH1 (Figure 5B). TNRFSF11B/Osteoprotegerin (OPG) is a
secreted decoy receptor that competes for the binding of RANKLs is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 4: Dedifferentiation is a reversible state. EndoC-bH1 cells were cultured for 3 or 14 days in control conditions (white columns), with FGF2 (gray columns) or for 3 days
with FGF2 followed by 11 days without FGF2 (dashed columns). INS, MAFA, SOX9 and MAFA levels were analyzed by RT-qPCR at day 3 and day 14. Data are represented as
mean  SD. n ¼ 5 biological replicates. **p < 0.01, ***p < 0.001.(TNFSF11) to its receptor RANK (TNFRSF11A). Transcriptomic and
qPCR data indicated that EndoC-bH1 expressed RANK, but not RANKL
(Figure 5C,D). RANK expressed in EndoC-bH1 was functional as
exogenous RANKL phosphorylated P38 in a dose-dependent manner
(Figure 5E). Moreover, exogenous OPG blocked the phosphorylation of
P38 by RANKL (Figure 5F). Remarkably, FGF2 that induced OPG
expression also prevented the P38 phosphorylation by RANKL
(Figure 5G).
3.6. Human pancreatic islets respond to FGF2 in a similar manner
to EndoC-bH1
We next tested the effect of FGF2 on primary human islet cell differ-
entiation status. We treated human islets with FGF2 for 72 h. As
observed with EndoC-bH1, following FGF2 treatment, MAFA and PAX6
mRNA levels signiﬁcantly decreased, while the expression of b cell
markers such as PDX1 and ABCC8 was notably stable (Figure 6A).
Decreased MAFA and stable PDX1 protein levels were observed in
parallel (Figure 6B). We next tested whether FGF2 treatment induced
SOX9 expression in human islet cells. First, RT-qPCR conﬁrmedMOLECULAR METABOLISM- (2018) 1e13  2018 The Authors. Published by Elsevier GmbH. This is an ope
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FGF2 treatment, although to lower extents than in EndoC-bH1
(Figure 6A). Double immunostaining for Chromogranin A and SOX9
indicated mutually exclusive expression in control pancreatic islets:
Chromogranin A was observed in endocrine pancreatic islets cells,
whereas almost no SOX9 staining was detected (Figure 6C). By
contrast, FGF2-treated islets displayed an increased SOX9 staining and
revealed cells that were double positive for both Chromogranin A and
SOX9 (Figure 6C), thus conﬁrming SOX9 induction in primary human
islet cells, similarly to observations in EndoC-bH1 cells. Furthermore,
human islets expressed mRNA for both RANK and RANKL (Fig. S5) and
showed FGF2 induction of TNRFSF11B (Figure 6D).
3.7. Upregulation of the FGF2 pathway and dedifferentiation
markers in human type 2 diabetes
Finally, we analyzed previously published transcriptomic data to ask
whether the pancreatic FGF pathway and dedifferentiation markers
were activated in patients with type 2 diabetes. Remarkably, single
cells RNA-Seq data [27] revealed an increase of FGF2 expression inn access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 7
Figure 5: FGF2-induced OPG (TNFRSF11B) blunts RANKL (TNFSF11) signaling. (A) Time dependent induction of OPG mRNA by FGF2 assessed by RNA-Seq in EndoC-bH1.
Closed circles: control; open circles: FGF2. (B) RT-qPCR analysis of OPG expression following 72 h treatment with FGF2 of EndoC-bH1. (C, D) RANK and RANKL expression in
EndoC-bH1 assessed by RNA-Seq (C) and RT-qPCR (D). (E) RANKL phosphorylates P38 in EndoC-bH1 in a concentration-dependent manner (15min treatment). (F) Exogenous OPG
blocks the phosphorylation of P38 by RANKL in EndoC-bH1. (G) Western-Blot and quantiﬁcation of phospho-P38 after 15min RANKL (100 ng/mL) incubation, in control EndoC-bH1
or EndoC-bH1 pre-treated by FGF2 during three days. Data are represented as mean  SD. n ¼ 5 biological replicates. **p < 0.01, ***p < 0.001. For Western Blot, representative
blot of n ¼ 5 experiments.
Original Articlepancreatic ductal, endothelial and pancreatic stellate cells from type 2
diabetic patients (Figure 7A). Moreover, analysis of microarray islets
data [29] revealed increased of FGFR1 mRNA levels in human islets
from type 2 diabetic compared with non-diabetic individuals, and also
SOX9 and HES1 expression (Figure 7BeD).8 MOLECULAR METABOLISM- (2018) 1e13  2018 The Authors. Published by Elsevier GmbH. Thi4. DISCUSSION
Here, we validated the recently developed human b cell line EndoC-bH1
as a model system to analyze human pancreatic b cell dedifferentiation.
As EndoC-bH1 were derived from a human fetal pancreas, they mights is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 6: Human pancreatic islets respond to FGF2 in a similar manner than EndoC-bH1. Human islets were exposed to FGF2 for 3 days. (A) MAFA, PAX6, PDX1, and ABCC8
mRNA levels were measured by RT-qPCR. (B) MAFA and PDX1 levels were analyzed by Western Blot. (C) SOX9 (green) in and CHGA (red) were analyzed by immunohistochemistry.
Scale bar: 60 mm. (D) RT-qPCR analysis of OPG expression following 72 h treatment of human islets with FGF2. Data are represented as mean  SD. n ¼ 5 biological replicates.
*p < 0.05, **p < 0.01, ***p < 0.001.be more prone to dedifferentiation to a developmental phenotype.
Conﬁrmation of our data using human islets, thus, was of importance.
We discovered that following FGF1 and FGF2 treatment, the expression
of many b cell speciﬁc markers is decreased. We also discovered new
positive markers of human b cell dedifferentiation, which translated to
primary human islets. Importantly, the dedifferentiation processMOLECULAR METABOLISM- (2018) 1e13  2018 The Authors. Published by Elsevier GmbH. This is an ope
www.molecularmetabolism.comobserved following FGF treatment was reversible. Our data also indi-
cated that human b cell dedifferentiation was paralleled by an increased
expression of TNFRSF11B, which encodes a decoy receptor that blocks
the RANK-RANKL interaction. Finally, we highlighted in transcriptomic
from type 2 diabetic islets an increase of the FGF2 pathway as well as
positive dedifferentiation markers.n access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 9
Figure 7: FGF pathway and dedifferentiation markers in type 2 diabetic islets. (A) FGF2 expression levels across pancreatic cell types from healthy and type 2 diabetic
individuals [27]. (B) FGFR1, (C) SOX9, and (D) HES1 mRNA expression in type 2 diabetic and non-diabetic isolated human islets assessed by microarray analysis [29]. **p < 0.01,
***p < 0.001.
Original ArticleBy comparing various culture conditions, we discovered that treatment
with either FGF1 or FGF2 decreased the expression of a large set of b
cell speciﬁc markers in a time- and concentration-dependent manner.
These markers included the transcription factor MAFA whose loss of
function in murine models leads to a decreased b cell identity [30,31],
and PAX6, recently identiﬁed as a key factor that maintains b cell
identity by repressing genes of other islet cell types in rodents [32].
4.1. Dedifferentiation through FGFR1c
We propose that FGF1 and FGF2 act through FGFR1c to induce
dedifferentiation. Indeed, while FGF1 can signal through each of the 7
FGFR, FGF2 speciﬁcally binds the c forms of FGFR, namely FGFR1c,
FGFR2c, and FGFR3c [23]. As our data indicate that EndoC-bH1 cells
mainly express FGFR1c among the FGF2 receptors, we can propose
that FGF2 binds FGFR1c to induce dedifferentiation. Interestingly, we
have evidence that the FGF2 actions required the activation of the
MAPK signaling because dedifferentiation is inhibited by a pretreat-
ment with a MAPK inhibitor.10 MOLECULAR METABOLISM- (2018) 1e13  2018 The Authors. Published by Elsevier GmbH. Thi4.2. New positive markers of b cell dedifferentiation
Dedifferentiated rodent b cells express a number of non-b cell genes
[3,30,33]. On the other hand, the number of markers with increased
expression in dedifferentiated human b cells that could be used as
positive markers of dedifferentiation is extremely limited. A recent study
reported ALDH1A3 as the ﬁrst positive marker of dedifferentiated human
beta cells from type 2 diabetic patients [7]. Our global transcriptomic
analyses of EndoC-bH1 cells treated with FGF2 allowed us to discover
additional markers of dedifferentiation. We found SOX9, HES1, MYC,
GAST, PYY, and NEUROG3 as potential new positive markers of dedif-
ferentiation. SOX9 and HES1 are transcription factors that are absent from
human pancreatic endocrine cells but expressed by exocrine cells in the
adult pancreas [27]. Here, we demonstrate that treatment with FGFs
induces SOX9 expression in both human b cell lines and in primary
endocrine cells (Chromogranin A-positive) from human islets. This in-
ductionwas not paralleled by an activation of pancreatic exocrinemarkers
such as AMY2B, CPA1, CFTR or SPP1, suggesting that FGF treatment
does not trans-differentiate b cells towards an exocrine phenotype.s is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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4.3. Dedifferentiated b cells revert to progenitor-like cells
SOX9 is expressed by pancreatic progenitor cells during prenatal life
[34]. Interestingly, we observed that FGF treatment induces the
expression in b cells of a set of markers that are normally expressed
either in pancreatic endocrine progenitors, or in b cells during early
life. This is for example the case for NEUROG3, a marker of endocrine
progenitor cells. While induction of Neurog3 expression has been
described in dedifferentiated b cells in rodents [3,35], determining
whether NEUROG3 levels increase when human b cells dedifferentiate
had been technically challenging [4]. Here, we observed that NEUROG3
expression is induced in a model of FGF-mediated human b cell
dedifferentiation. In parallel to NEUROG3 induction, we also observed
an activation of gastrin expression following FGF treatment. Gastrin is a
stomach hormone known for a long time to be transiently expressed
during fetal and perinatal life in the rat pancreas with expression
decreasing thereafter [25]. Interestingly, it was recently demonstrated
that gastrin is re-expressed in b cells in rodent and human with type 2
diabetes [36]. Therefore, gastrin may represent a novel biomarker of
dedifferentiated human b cells. Taken together, we propose that upon
dedifferentiation, human b cells express markers of pancreatic pro-
genitors, such as SOX9 and HES1, of endocrine progenitors such as
NEUROG3 and of perinatal b cells such as gastrin.
4.4. b cell dedifferentiation is reversible
The vast majority of data related to b cell dedifferentiation has been
generated from in vivo mice models; thus, the process of dedifferen-
tiation has been analyzed at a limited number of time points [30,33].
While it has been proposed that loss of differentiation markers precedes
the expression of markers of progenitor cells, this hypothesis has not
been fully validated [3]. Here, by constructing and validating an in vitro
model of human b cell dedifferentiation, we were able to efﬁciently
study dedifferentiation at different time points. Using our model, we
demonstrated that loss of expression of b cell speciﬁc markers such as
MAFA, ZNT8, GCK or SLC2A2, clearly preceded the induction of non-b
cell genes such as neurogenin3 or gastrin. Whether loss of expression
of b cell speciﬁc genes is necessary for the induction of non-b cell
genes remains to be determined. Of interest, we also observed that
when EndoC-bH1 cells were ﬁrst treated with FGFs that was followed
by a washout treatment, the dedifferentiation state was reverted. It
should now be tested on human islet preparations. Accordingly, rodent
data indicate that dedifferentiated b cells can redifferentiate to mature
insulin-positive b cells following insulin therapy [5] or diet [37,38].
Human data also support the concept of reversibility of dedifferentiated
b cells [39,40]. The mechanisms that allow rodent cells to redifferen-
tiate into b cells remain partly unexplored, and human data are even
scarcer. Our FGF-dependent model of human b cells dedifferentiation-
redifferentiation should permit to progress on this topic and to specify
additional ways to efﬁciently reverse dedifferentiation in human b cells.
4.5. Dedifferentiation state alters extracellular signaling
Dedifferentiation could also represent a mechanism to protect b cells
against the deleterious effects of extracellular signals. OPG is a soluble
decoy receptor that binds RANKL and inhibits its interaction with its
receptor, RANK [41]. OPG is expressed by pancreatic islet cells, and
up-regulated in models of b cell proliferation [42,43]. OPG has also
recently been described as a target of lactogen in b cells and is
required for lactogen-induced b cell proliferation [44]. Here, we
demonstrate that human b cells express a functional RANK signaling
pathway. Interestingly, FGF2 induces the expression of OPG in EndoC-
bH1 and in human islets and blunts the RANK-RANKL signaling
pathway. Taken together, induction of OPG during dedifferentiationMOLECULAR METABOLISM- (2018) 1e13  2018 The Authors. Published by Elsevier GmbH. This is an ope
www.molecularmetabolism.comcould have a protective effect against deleterious signaling through the
RANK-signaling pathway.
4.6. FGF2 and dedifferentiation during type 2 diabetes
In this work, to model dedifferentiation and to discover positive
markers of human b cell dedifferentiation, we have used FGF treat-
ment. The FGF pathway previously has been demonstrated to be
involved in maintaining b cell mass in mice [45]. Interestingly, FGF1 is
selectively induced in visceral fat in response to a high-fat diet in mice
[46], and peri- and intra-pancreatic visceral fat correlates with age and
body mass index, two major risk factors for type 2 diabetes [47].
Moreover, our analysis of available transcriptomic data [27] indicates
that FGF2 expression is increased in several non-islets cell types in
T2D pancreata, including ductal, endothelial, and pancreatic stellate
cells, while FGFR1 is increased in islets from T2D patients. We thus
hypothesize that an excess pancreatic FGF can contribute to b cell
dedifferentiation, worsening type 2 diabetes. Intriguingly, FGF1 levels
are elevated in newly diagnosed cases of type 2 diabetes as compared
to normal glucose tolerance controls [48].
4.7. Conclusion
In conclusion, this work models b cell dedifferentiation in a human
context. It implicates FGF signaling in this process. Our model, char-
acterization of dedifferentiation markers, and identiﬁcation on FGF2 as
a modulator, could lead to new interventions to protect human b cells
against dedifferentiation.
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